

NANOTECHNOLOGY IN ONCOLOGY. Radiosensitization with gold nanoparticles (GNP) as an almost perfect example

Branislav Jeremic, MD, PhD

Professor and Head Division of Radiation Oncology Stellenbosch University and Tygerberg Hospital Cape Town South Africa



CONFLICT OF INTEREST

NONE TO DECLARE



Design, characterization, production and application of

structures, devices and systems


by controlling shape and size

at a nanometric scale



Size and scale of nanostructures relative to commonly known objects.

Nanoscale reference



Particles with lengths 1-100nm in 2 to 3 dimensions

Kateb et al. NeuroImage, 54, Suppl 1, 2011.



- DISTINCT GEOMETRIES
- SPECIFIC SURFACE PROPERTIES AND CONDUCTIVITIES
- SUSCEPTIBILITY TO VARIOUS ENVIRONMENTAL STIMULI (light or heat)


ALL CAN BE CONTROLLED!



USE OF NANOMATERIALS



- BECOME FREQUENT IN RECENT YEARS
- IMAGING, DRUG AND GENE DELIVERY






USE OF NANOMATERIALS



- BECOME FREQUENT IN RECENT YEARS
- IMAGING, DRUG AND GENE DELIVERY





DELIVERY AND ACCUMULATION

А Nanostructures travel through the bloodstream and are designed to target specific tissues types and disease processes Nanostructures **Targeted tissue** в Nanoshells Nanoshells accumulate in target tissue, enhance imaging Gold shell and deliver therapeutic agents Core Target С Quantum dots Quantum dots accumulate in target tissue, emit flourescence in response to light Antibody coating Core Shell Target D Nanoparticles Nanoparticles deliver Polyethylene therapeutic agents to target glycol (PEG) stalk Therapeutic core Receptor Targeting molecule Therapeutic Target





Unique physiochemical properties surface plasmon resonance (SPR) ability to bind amine and thiol groups

Allows surface modification!





Used in various anticancer approaches

Used in metal-enhanced RT


Exploits ability of high Z materials to preferentially increase photoelectric absorption of low kV RT (vs soft tissues)

Leads to enhanced – RT dose deposition at the interface of surrounding tissues




USE OF GOLD NANOSTRUCTURES











Presence in target cells necessary for radiosensitization

Important processes:

intracellular uptake transport processing



RELEVANT FEATURES OF GNP ENHANCEMENT OF RT EFFECTS



Intracellular uptake, transport and processing	Endocytosis	One of the major pathways for uptake Internalization is likely Receptor-mediated endocytosis (RME)
		Rate and extent of GNP uptake: size, shape, surface-coating and charge-dependent
	Intracellular processing	Processing difference between targeted and untargeted GNPs (untargeted GNPs have slower diffusion in in cell cytoplasm)
		Organelle distribution also influenced by uptake mechanism (slower diffusion time for GNPs in lysosomes than in endosomes)




RELEVANT FEATURES OF GNP ENHANCEMENT OF RT EFFECTS



Intracellular uptake, transport and processing	Exocytosis	Energy-dependent process
		Dependent on time, size and shape of GNP (better and faster for smaller GNPs; better for GNRs than spherical GNPs)
	Nuclear targeting	GNP surface modification allows crossing cell membrane, but avoiding endocytosis
		Improves nuclear delivery, but needs conjugation with nuclear targeting peptides
		Size-dependent process



PATHWAYS AND PROCESSES INSIDE THE CELL




endo-lysosomal pathway of NPs inside the cell

RME process of NPs inside the cell



Different stages of NP transport through the cell




INTERACTION BETWEEN PROTEINS (LIGANDS) ON THE CELL MEMBRANE AND CELL MEMBRANE RECEPTORS

GNPs LOCALIZATION IN ENDOSOMES


FUSION WITH LYSOSOMES TO BE DEGRADED



EFFECTS OF SURFACE CHARGE AND SIZE



Effect of surface charge of GNPs on cell uptake – interactions between cell membrane interactions and GNPs with different surface charges



Effect of NP surface charge (top) and size (bottom) of NP on protein structure (top)




RELEVANT FEATURES OF GNP ENHANCEMENT OF RT EFFECTS



Mechanisms of GNP-RT enhancement	RT-induced cell-killing occurs after the damage to DNA, mitochondria and the cell membrane Induction of apoptosis and necrosis implicated in the
	process of cell damage
	Cell cycle synchronization (accumulation in G2/M)
	Elevated oxydative stress
	Production of low energy electrons (LEEs) (<20 to <200eV) important aspect of cell damage
	Dependent of many factors such as energy, size and concentration of Gold



Mechanisms of GNP-RT enhancement





RELEVANT FEATURES OF GNP ENHANCEMENT OF RT EFFECTS




Irradiation energy	Most favorable effects of kV energies, but merging data point to the successful use of MV energies Experimental range of DEFs range: 1.01 (MV) to 2.11-7.5 (kV)
	With recently manufactured Linacs with FFF and with anticancer drugs, clinical application likely
	Dependent on many other factors such as Gold concentration, size, shape



IRRADIATION ENERGY

- Endothelial dose enhancement factor (EDEF) was 1.2 4.4
- It came mostly from the low energy (ca. 100 kV) spectrum






RELEVANT FEATURES OF GNP ENHANCEMENT OF RT EFFECTS



GNP size, shape and toxicity	Need to compromise between GNP size, and other factors influencing their metabolism, distribution and internalization realized
	Shape and surface attachments also important factors when discussing RT-enhancement effects
	 Toxicity dependent on: shape (GNRs vs GNPs) size (smaller GNPs can also be toxic) surface characteristics (PEGylated without spleen/kidney damage) dose (in vitro not toxic at < 250 mM, ionic Au toxic at 25 mM) administration route (more in oral and IP)




PEGylated GNPs – toxicity on various organs



Various size PEG-coated gold NPs treated mice. Kidney and spleen don't show appreciable pathological changes, while liver does.

Zhang X-D et al, Biomaterials, 33: 6408 – 6419, 2012.

S Toxicity dependence on protection type (GSH vs BSA)



GSH- and BSA-protected Au 25 NCs after 28 days. Appreciable pathological changes have been found only in liver in the BSA-protected Au 25 NCs.

Xiao-Dong et al. Biomaterials, 33: 4628 – 4638, 2012,




RELEVANT FEATURES OF GNP ENHANCEMENT OF RT EFFECTS




GNP-RTR-anticancer drugs	Few data available, though of potentially substantial application in daily clinical practice
	Cisplatin shown to significantly enhance RT effects
	Capture of LEE at the site of CDDP significantly enhanced backbone rapture
	CDDP-DNA complex + GNP : DEFs range 3.0 – 7.5

S RT + CHEMO/TARGETED DRUGS





Radiation alone (R) vs combined with NLE-CDDP (NLE-CDDP + R) vs CDDP (CDDP + R)



P = 0.00 for CDDP vs R; P = 0.00 for NLE-CDDP vs R; P = 0.043 for CDDP vs NLE-CDDP

Zhang et al, In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer. Int J Nanomed, 6:437-444, 2011





- A phase I feasibility trial (8 pts) (Rose et al, IJROBP, 1999)
- WBRT (40Gy in 20 fx in 4 weeks) + boost of 3-5 weekly 5 Gy/fx
- IV iodine contrast administered prior to rotational RT (360 degrees, three planes, 140KV)
- Response of intracranial mets measured by weekly CT scans
- I CR and 4 PR, accompanied with no increase of side effects



RT-GNP - CLINICAL ASPECTS



- CYT-6091, 27 nm citrate-coated GNPs bound with thiolated PEG and tumor necrosis factor- α (TNF- α)
- 29 pts with various solid cancers unresponsive to previous Tx
- TNF- α 50-600 µg/sqm with no dose-limiting toxicities
- The main side-effect being grade II fever
- I PR and 3 SD observed during this study



RT-GNP - CLINICAL ASPECTS

- Pilot study, IV administared Auroshell® particles with photodermal therapy
- Pts with recurrent or refractory H&N cancer
- Interstitial illumination of Auroshell® particles with 808nm laser used
- Post-treatment tumor biopsies to document both nanoparticle and tumor response.

(NCT00848042) at www.clinicaltrials.gov



RT-GNP - CLINICAL ASPECTS



• AuroLase therapy in pts with primary and/or metastatic lung tumors

• IV of AuroShell particles followed by laser illumination for photothermal ablation

(NCT01679470) at www.clinicaltrials.gov





- Advantage of kV RT skin and superficial tumours?
- Melanoma, Kaposi sarcoma, H&N nodes, chest wall recurrences, other...?
- MV RT with DEF of 1.1-1.3 means 10-30% less RT dose
- In practice, DEF of 1.2 means decrease from 72 Gy to 60 Gy
- Consider chemo as additional RT- enhancer in deep seated cancers
- Trials needed!

Gracias!

